ZA201300822B - Diphenyl either compounds for the teatment of liver,lung disorders, diabetic complications and cardiovascular deseases - Google Patents
Diphenyl either compounds for the teatment of liver,lung disorders, diabetic complications and cardiovascular deseasesInfo
- Publication number
- ZA201300822B ZA201300822B ZA2013/00822A ZA201300822A ZA201300822B ZA 201300822 B ZA201300822 B ZA 201300822B ZA 2013/00822 A ZA2013/00822 A ZA 2013/00822A ZA 201300822 A ZA201300822 A ZA 201300822A ZA 201300822 B ZA201300822 B ZA 201300822B
- Authority
- ZA
- South Africa
- Prior art keywords
- teatment
- deseases
- cardiovascular
- diphenyl
- liver
- Prior art date
Links
- 208000002249 Diabetes Complications Diseases 0.000 title 1
- 206010012655 Diabetic complications Diseases 0.000 title 1
- 208000019693 Lung disease Diseases 0.000 title 1
- 235000010290 biphenyl Nutrition 0.000 title 1
- 239000004305 biphenyl Substances 0.000 title 1
- 125000006267 biphenyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2140CH2010 | 2010-07-28 | ||
| IN525CH2011 | 2011-02-23 | ||
| PCT/IN2011/000210 WO2012014218A1 (en) | 2010-07-28 | 2011-03-28 | Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201300822B true ZA201300822B (en) | 2014-04-30 |
Family
ID=44247871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2013/00822A ZA201300822B (en) | 2010-07-28 | 2013-01-31 | Diphenyl either compounds for the teatment of liver,lung disorders, diabetic complications and cardiovascular deseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140187594A1 (enExample) |
| EP (2) | EP2987488A1 (enExample) |
| JP (1) | JP5957452B2 (enExample) |
| CN (1) | CN103108634B (enExample) |
| AU (1) | AU2011284256B8 (enExample) |
| CA (1) | CA2805245A1 (enExample) |
| ES (1) | ES2565487T3 (enExample) |
| HU (1) | HUE028725T2 (enExample) |
| PL (1) | PL2598142T3 (enExample) |
| WO (1) | WO2012014218A1 (enExample) |
| ZA (1) | ZA201300822B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3362053A4 (en) * | 2015-10-16 | 2019-04-17 | Hadasit Medical Research Services and Development Ltd. | TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE |
| TWI762634B (zh) | 2017-05-05 | 2022-05-01 | 大陸商上海赫普化醫藥技術有限公司 | 胺基-芳基-苯甲醯胺化合物及其使用方法 |
| CN113750089B (zh) * | 2021-10-13 | 2023-09-19 | 南方医科大学南方医院 | 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗慢性肝病的药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08109175A (ja) * | 1994-10-07 | 1996-04-30 | Torii Yakuhin Kk | チアゾリジン−２−オンエステル誘導体 |
| US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
| US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
| US6794401B2 (en) | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| JP2008533122A (ja) * | 2005-03-18 | 2008-08-21 | オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド | 新規なチロシン誘導体 |
| WO2006138475A2 (en) * | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| WO2008106166A2 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors |
| JP2010520306A (ja) * | 2007-03-07 | 2010-06-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | エストロゲン関連受容体−αモジュレーターとしての置換フェノキシチアゾリジンジオン |
| WO2009030968A1 (en) * | 2007-09-05 | 2009-03-12 | Orchid Research Laboratories Limited | Mao a inhibitors with a diphenyl ether-substructure. |
| WO2009070781A1 (en) * | 2007-11-30 | 2009-06-04 | The Regents Of The University Of California | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products |
-
2011
- 2011-03-28 US US13/809,604 patent/US20140187594A1/en not_active Abandoned
- 2011-03-28 EP EP15189194.2A patent/EP2987488A1/en not_active Withdrawn
- 2011-03-28 WO PCT/IN2011/000210 patent/WO2012014218A1/en not_active Ceased
- 2011-03-28 HU HUE11720594A patent/HUE028725T2/en unknown
- 2011-03-28 CN CN201180037004.1A patent/CN103108634B/zh not_active Expired - Fee Related
- 2011-03-28 EP EP11720594.8A patent/EP2598142B1/en not_active Not-in-force
- 2011-03-28 AU AU2011284256A patent/AU2011284256B8/en not_active Ceased
- 2011-03-28 PL PL11720594T patent/PL2598142T3/pl unknown
- 2011-03-28 JP JP2013521285A patent/JP5957452B2/ja not_active Expired - Fee Related
- 2011-03-28 ES ES11720594.8T patent/ES2565487T3/es active Active
- 2011-03-28 CA CA2805245A patent/CA2805245A1/en not_active Abandoned
-
2013
- 2013-01-31 ZA ZA2013/00822A patent/ZA201300822B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013532682A (ja) | 2013-08-19 |
| AU2011284256B2 (en) | 2014-05-29 |
| CN103108634A (zh) | 2013-05-15 |
| ES2565487T3 (es) | 2016-04-05 |
| US20140187594A1 (en) | 2014-07-03 |
| AU2011284256A1 (en) | 2013-02-14 |
| AU2011284256B8 (en) | 2014-11-13 |
| WO2012014218A1 (en) | 2012-02-02 |
| CA2805245A1 (en) | 2012-02-02 |
| EP2987488A1 (en) | 2016-02-24 |
| CN103108634B (zh) | 2015-08-12 |
| HUE028725T2 (en) | 2016-12-28 |
| AU2011284256A8 (en) | 2014-11-13 |
| JP5957452B2 (ja) | 2016-07-27 |
| EP2598142B1 (en) | 2015-12-16 |
| EP2598142A1 (en) | 2013-06-05 |
| PL2598142T3 (pl) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2646425T3 (pl) | Kwasy indanyloksydihydrobenzofuranylooctowe użyteczne do leczenia zespołu metabolicznego | |
| EP2669289A4 (en) | QUINOLINE-LIKE COMPOUND CONTAINING A PHOSPHORUS-SUBSTITUTED GROUP, PREPARATION METHOD, MEDICAL COMPOSITION CONTAINING THE COMPOUND, AND APPLICATION | |
| WO2011140517A9 (en) | Methods for treating diseases of the lung | |
| EP2579809A4 (en) | Vascular elastance | |
| ZA201100653B (en) | Topical composition for the treatment of ctinic keratosis | |
| WO2012021287A9 (en) | Methods for the treatment and prevention of metabolic disorders | |
| GB201016279D0 (en) | Stiffener run-out | |
| IL226386A0 (en) | Medical treatment for metabolic syndrome, type 2 diabetes, obesity or pre-diabetes | |
| SI2575769T1 (sl) | Stabilizirani sestavek takrolimusa | |
| PT2747592T (pt) | Sapato e método para a respectiva construção | |
| ZA201207375B (en) | Stabilized pharmaceutical composition | |
| EP2733156A4 (en) | ORGANIC-INORGANIC COMPLEX AND COMPOSITION FOR THE FORMATION OF THIS COMPLEX | |
| ZA201308776B (en) | Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome | |
| EP2995614B8 (en) | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof | |
| ZA201209038B (en) | Adhesive slow-release formulations for the local administration of curcumin | |
| EP2549889A4 (en) | METHOD FOR IMPROVING THE TASTE OF ESTABLISHABLE COMPOSITIONS | |
| PL2598142T3 (pl) | Związki eteru difenylowego do zastosowania w leczeniu zaburzeń wątroby | |
| PT2460509T (pt) | Composição para tratamento de verrugas | |
| PL393268A1 (pl) | Kwas 2-amino-6-dihydroksyborylo-1,2,3,4-tetrahydronaftaleno-2-karboksylowy i sposób jego wytwarzania | |
| GB201006166D0 (en) | Compounds for the treatment of metabolic disorders | |
| EP2578206A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER PART OF THE UROGENITAL SYSTEM | |
| AU2013204097B2 (en) | Pharmaceutical composition | |
| AU2013204095B2 (en) | Pharmaceutical composition | |
| PT2558079T (pt) | Composição de xarope seco de ciprofloxacina | |
| HK1178759A (en) | Upper structure for footwear and footwear comprising the same |